Oramed Pharm (ORMP) AI Stock Analysis

Compare

523 Followers

Top Page

Oramed Pharm

(NASDAQ:ORMP)

Rating:47Neutral

Price Target:―

Oramed Pharm's overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.

Positive Factors

Investment

The joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.

Joint Venture

Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.

Negative Factors

Clinical Efficacy

The candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.

Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$87.42M

Dividend YieldN/A

Average Volume (3M)62.54K

Price to Earnings (P/E)21.1

Beta (1Y)0.91

Revenue Growth-100.00%

EPS GrowthN/A

CountryUS

Employees13

SectorHealthcare

Sector Strength44

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.48

Shares Outstanding40,850,456

10 Day Avg. Volume56,578

30 Day Avg. Volume62,538

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)0.58

Price to Sales (P/S)0.00

P/FCF Ratio-11.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Oramed Pharm Business Overview & Revenue Model

Company DescriptionOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

How the Company Makes MoneyOramed Pharmaceuticals generates revenue primarily through the development and potential commercialization of its oral drug delivery technology. The company's revenue model is heavily reliant on successful clinical trials and the subsequent approval and licensing of its products. Oramed partners with pharmaceutical companies to co-develop and license its technologies, receiving milestone payments and royalties from these collaborations. Additionally, the company may engage in research and development service agreements, contributing to its revenue streams. However, as a clinical-stage company, its current earnings are mostly derived from partnerships and investments aimed at advancing its clinical programs.

Oramed Pharm Financial Statement Overview

Summary

Oramed Pharm's financial performance is mixed. The income statement is weak due to zero revenue and negative EBIT, while the balance sheet is strong with a high equity ratio. Cash flow is negative, indicating liquidity issues.

Income Statement

Negative

Oramed Pharm's income statement reflects significant challenges, primarily due to zero revenue in the TTM, a negative EBIT, and fluctuating net income figures. The lack of revenue growth and negative margins highlight ongoing operational inefficiencies.

Balance Sheet

Neutral

The balance sheet shows a strong equity position with a high equity ratio, indicative of financial stability. However, the debt-to-equity ratio is low, providing some leverage risk, but overall liabilities remain manageable relative to equity.

Cash Flow

Negative

Cash flow analysis reveals negative operating and free cash flows, indicating potential liquidity issues. The operating cash flow to net income ratio is unfavorable, suggesting challenges in converting income into cash flow.

TTM	Dec 2023	Dec 2022	Sep 2021	Sep 2020	Sep 2019
Breakdown
Income Statement		Total Revenue
0.00	1.34M	2.70M	2.70M	2.71M	2.70M
	Gross Profit
0.00	1.34M	2.70M	2.70M	2.62M	2.61M
	EBIT
-13.06M	-15.77M	-40.60M	-24.22M	-11.76M	-14.63M
	EBITDA
24.86M	-15.57M	-36.98M	-25.04M	-11.31M	-14.17M
	Net Income Common Stockholders
4.46M	5.53M	-37.76M	-22.24M	-11.51M	-14.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.34M	162.05M	155.72M	94.14M	39.90M	32.28M
	Total Assets
5.96M	220.55M	161.64M	128.00M	44.63M	34.66M
	Total Debt
0.00	51.62M	894.00K	533.00K	75.00K	0.00
	Net Debt
-2.04M	42.57M	-39.57M	-76.71M	-19.22M	-3.33M
	Total Liabilities
709.29K	57.66M	10.49M	11.48M	11.75M	15.27M
	Stockholders Equity
5.25M	163.82M	151.81M	115.77M	32.88M	19.39M
Cash Flow		Free Cash Flow
-7.93M	-10.55M	-28.41M	-21.56M	-12.52M	-12.96M
	Operating Cash Flow
-7.92M	-10.29M	-27.92M	-21.18M	-12.44M	-12.94M
	Investing Cash Flow
120.39M	-73.04M	30.21M	-23.76M	4.63M	11.26M
	Financing Cash Flow
-75.84M	51.98M	10.78M	102.89M	23.79M	0.00

Oramed Pharm Technical Analysis

Technical Analysis Sentiment

Negative

Last Price2.11

Price Trends

50DMA

2.25

Negative

100DMA

2.28

Negative

200DMA

2.33

Negative

Market Momentum

MACD

-0.03

Positive

RSI

38.29

Neutral

STOCH

12.86

Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Negative. The current price of 2.11 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.25, and below the 200-day MA of 2.33, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 38.29 is Neutral, neither overbought nor oversold. The STOCH value of 12.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORMP.

Oramed Pharm Risk Analysis

Oramed Pharm disclosed 45 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Oramed Pharm Peers Comparison

Overall Rating

UnderperformOutperform

Sector (53)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
ORMP	47 Neutral	$87.42M	21.10	-18.37%	―	-100.00%	―
XBIT		$93.60M	―	-20.53%	―	―	―
TLSA		$164.96M	―		―	―	―
CLYM	41 Neutral	$85.82M	―	-62.04%	―	―	-61.95%
KYTX	36 Underperform	$103.29M	―	-49.72%	―	―	―
GNLX	33 Underperform	$98.49M	―	-131.36%	―	-100.00%	9.16%

* Healthcare Sector Average

Performance Comparison

ORMP

Oramed Pharm

2.11

-0.19

-8.26%

XBIT

XBiotech

2.87

-5.72

-66.59%

TLSA

Tiziana Life Sciences

1.42

0.61

75.31%

CLYM

Climb Bio

1.21

-6.66

-84.63%

GNLX

Genelux Corp.

2.49

-2.37

-48.77%

KYTX

Kyverna Therapeutics, Inc.

2.21

-11.12

-83.42%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.